A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial
J. Pujol, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot +18 more

